Burning Rock Biotech Ltd
NASDAQ:BNR
ROA
Return on Assets
ROA, or Return on Assets, is an indicator of how well a company utilizes its assets in terms of profitability. This number tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. A higher ROA indicates more efficient use of assets to produce earnings, making it a valuable gauge for investors assessing a company's operational efficiency and profitability potential.
ROA Across Competitors
| Country | Company | Market Cap | ROA | ||
|---|---|---|---|---|---|
| CN |
|
Burning Rock Biotech Ltd
NASDAQ:BNR
|
31.4m USD |
-36%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-391%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
323.4B USD |
3%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
149.7B USD |
7%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
135B USD |
11%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.4B USD |
-4%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-67%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
119.9B AUD |
7%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
64B USD |
13%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-21%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
37.2B USD |
-7%
|
Burning Rock Biotech Ltd
Glance View
Burning Rock Biotech Ltd. engages in the investment of medical fields. The company is headquartered in Guangzhou, Guangdong. The company went IPO on 2020-06-12. The firm operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The firm mainly conducts its businesses in the China market.
See Also
ROA, or Return on Assets, is an indicator of how well a company utilizes its assets in terms of profitability. This number tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. A higher ROA indicates more efficient use of assets to produce earnings, making it a valuable gauge for investors assessing a company's operational efficiency and profitability potential.
Based on Burning Rock Biotech Ltd's most recent financial statements, the company has ROA of -36.1%.
You don't have any saved screeners yet